Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), headquartered in Marlborough, Massachusetts, is a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapeutics. The company's proprietary INTASYL™ siRNA gene silencing technology is at the forefront of its efforts to enhance the effectiveness of immune cells in targeting and destroying tumor cells.
Phio's core product pipeline includes:
- PH-762: Targets the checkpoint protein PD-1 on immune cells, enhancing their ability to attack tumors. Currently in Phase 1b clinical trials, PH-762 is being tested for its efficacy in treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
- PH-804: Focuses on the suppressive immune receptor TIGIT, present on T cells and natural killer cells, to bolster immune responses against cancer.
- PH-790: Aims to silence the PD-L1 protein, which normally prevents immune cells from attacking non-harmful cells, thereby boosting the body's natural defenses against cancer.
Phio Pharmaceuticals collaborates with leading institutions such as Gustave Roussy, Medigene AG, and Helmholtz Zentrum München to advance their research and development efforts. The company's financial health, as of the latest reports, shows a cash position of $6.5 million, with a significant reduction in research and development expenses aimed at transitioning from discovery to product development.
Phio's latest updates include the presentation of new data on PH-762 at various scientific conferences and the initiation of new partnerships. These efforts underscore Phio's commitment to delivering cutting-edge cancer treatments and improving patient outcomes.
For more details, visit the company's website at www.phiopharma.com.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its Q3 2021 financial results, reporting a net loss of $3.7 million or $0.28 per share, an increase from $2.3 million or $0.40 per share for Q3 2020. Cash and cash equivalents stood at $26.5 million as of September 30, 2021, expected to last until Q2 2023. The company aims to commence its first-in-human trial for PH-762 in Q1 2022 and expects to file a clinical trial application for PH-894 in H2 2022, showcasing the potential of its INTASYL technology in immuno-oncology.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that new data indicates a systemic immune response can be triggered by its lead product candidate, PH-762, after local administration. These findings will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington, D.C. from November 10-14, 2021. The relevant poster presentation is scheduled for November 12, 2021, at 7:00 am ET, showcasing potential advancements in immuno-oncology therapy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced significant findings at the AACR-NCI-EORTC conference on October 7, 2021, regarding PH-894, its self-delivering RNAi compound targeting BRD4. The results indicate that PH-894 effectively silenced BRD4, enhancing T cell activation and tumor growth inhibition in vivo. This suggests PH-894 may serve as a promising immunotherapy option by reprogramming T cells. Phio is currently working on IND-enabling studies to advance PH-894 into clinical trials.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company specializing in immuno-oncology, announced two significant poster presentations at upcoming scientific conferences in October 2021. The first will occur at the AACR-NCI-EORTC Virtual International Conference from October 7-10, showcasing research on targeting BRD4 in T cells with self-delivering RNAi PH-894. The second presentation at the 8th Immunotherapy of Cancer Conference (ITOC8) on October 8-9 will focus on optimizing T lymphocytes for solid tumor therapy. For more details, visit their website.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced promising results from a study showcased at the ESMO Congress 2021. The study demonstrated that the INTASYL technology could cure tumors and elicit durable systemic immunity in a preclinical model targeting PD-1 and BRD4. Specifically, 83% of the treated animals showed complete tumor response, even with low dosage therapy. This research highlights INTASYL's potential as a versatile immuno-oncology therapeutic platform, with further clinical trials anticipated to validate its efficacy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13 to 15, 2021. Dr. Gerrit Dispersyn, President & CEO, will present on September 13 at 7:00 AM ET. A webcast of the presentation will be available, with replays accessible on the company's website for 90 days. Phio focuses on developing immuno-oncology therapeutics using its proprietary INTASYL platform, aimed at enhancing immune response against tumors.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced that it will present new clinical study data at the ESMO Virtual Congress 2021 from September 16-21, 2021. The presentation will focus on dual targeting PD-1 and BRD4 using the company's proprietary INTASYL self-delivering RNAi platform, aiming to elicit persistent anti-tumor immunity following tumor resolution. The abstract number for this presentation is #4154. Archived details will be available on the Company's website in the Investors section.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its financial results for Q2 2021, showing a net loss of $2.7 million. The company has $29.4 million in cash, sufficient to fund operations through Q2 2023. Phio is advancing its INTASYL™ platform, with promising preclinical data for its lead asset, PH-762, aimed at PD-1 in cancer treatment. Clinical trials are set to begin in 2022, with expected milestones including first-in-human studies for melanoma. R&D expenses increased to $1.7 million, reflecting expanded clinical preparation.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in a Fireside Chat with H.C. Wainwright on July 12, 2021, at 11 a.m. Eastern Time. The event aims to discuss the company’s advancements in immuno-oncology therapeutics utilizing its INTASYL™ RNAi platform, designed to boost immune responses against tumors. Interested listeners should register in advance to access the live audio. The webcast will be archived for 90 days on the company’s website. For more information on Phio's innovative therapies, visit their site.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced the rescheduling of its fireside chat with H.C. Wainwright, originally set for June 22, 2021. The new date is July 12, 2021, at 11 a.m. Eastern Time. Phio focuses on developing immuno-oncology therapeutics using its proprietary self-delivering RNAi (INTASYL™) platform, aimed at enhancing immune response against tumors. Investors can expect more details on the rescheduled event soon.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
What does Phio Pharmaceuticals Corp. do?
What is INTASYL™ technology?
What are Phio's key products?
Who are Phio's collaboration partners?
What recent achievements has Phio Pharmaceuticals announced?
What is the financial condition of Phio Pharmaceuticals?
What is PH-762?
What cancers is PH-762 being tested for?
What is the significance of INTASYL™ technology?
Where can I find more information about Phio Pharmaceuticals?
